表紙
市場調查報告書

特發性肺纖維化治療藥全球市場預測 (∼2029年):抗纖維化劑、酪胺酸激□抑制劑、抗炎症劑、免疫抑制劑、其他單株抗體 (MoA) 、創新藥物

Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2029: Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs

出版商 Visiongain Ltd 商品編碼 927159
出版日期 內容資訊 英文 171 Pages
商品交期: 最快1-2個工作天內
價格
特發性肺纖維化治療藥全球市場預測 (∼2029年):抗纖維化劑、酪胺酸激□抑制劑、抗炎症劑、免疫抑制劑、其他單株抗體 (MoA) 、創新藥物 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2029: Antifibrotics, Tyrosine Kinase Inhibitors, Anti-inflammatory Drugs, Immunosuppressants, Other MoA, Innovator Drugs
出版日期: 2019年11月26日內容資訊: 英文 171 Pages
簡介

預估全球特發性肺纖維化治療藥市場,在預測期間前半期將以16.7%的CAGR成長。 2018年抗纖維化劑維持最大市場占比(51%),其次為酪胺酸激□抑制劑。

本報告研究全球特發性肺纖維化治療藥市場,系統性彙整市場概要、按區分和區域的趨勢、以及市場投入企業簡介等情報。

第1章 報告概要

第2章 特發性肺纖維化(IPF)簡介

  • IPF為何?
  • 病因:原因和危險因子
  • 症狀
  • IPF病期
  • 診斷
    • 診斷測試
    • 肺功能檢測/肺功能檢測
    • 血氧飽和度
    • 肺活檢
    • 胸部X光
    • 電腦斷層攝影(CT)
    • 心臟超音波檢查
  • 流行病學
    • 方法論
    • 流行病學:按國家
    • 流行病學:按疾病重症度
    • 流行病學:按性別
    • 主要市場罹病率
    • 主要市場IPF預測
  • 人文和經濟負擔
    • 合併症
    • 死亡率
    • 醫療利用和經濟負擔
  • 預防和治療
    • 準則
    • 非藥理學管理
    • 藥理學治療

第3章 全球特發性肺纖維化治療藥:簡介

  • 市場結構
  • 市場定義與範圍
  • 按作用機制分類
    • 抗纖維化劑
    • 酪胺酸激□抑制劑
    • 抗炎症藥
    • 免疫抑制劑
    • 其他機制
  • 按創新藥或Off-label藥分類
    • 創新藥
    • Off-label藥

第4章 全球特發性肺纖維化治療藥市場預測

  • 全球市場:2016年
  • 全球市場預測 (2017∼2027年)
  • 全球市場區分:按作用機制
  • 全球市場:按作用機制
  • 按創新藥和Off-label藥的全球市場
  • 全球市場推動因素、阻礙因素、趨勢

第5章 主要特發性肺纖維化治療藥

  • 銷售、銷售實績、預測
    • Esbriet
    • Ofev
  • Off-label藥

第6章 主要國家市場

  • 區域細項
  • 市場預測:按區域
  • 美國市場
  • 歐洲5國市場
  • 日本市場
  • 其他國家市場

第7章 研發趨勢

  • PIPELINE藥劑的新作用機制
  • 矚目化合物
  • 具前景化合物
    • Phase III分子
    • Phase II分子
    • Phase I試驗

第8章 定價和醫療費用償付概要

  • Ofev
    • NICE(英國)
    • SMC(蘇格蘭)
    • PBAC(澳洲)
    • CADTH(加拿大)
    • G-BA(德國)
    • HAS(法國)
    • 整體HTA課題
  • Esbriet
    • NICE(英國)
    • SMC(蘇格蘭)
    • G-BA(德國)
    • HAS(法國)
    • CADTH(加拿大)

第9章 定性分析

  • SWOT分析

第10章 主要企業

  • Roche
  • Boehringer Ingelheim GmbH
  • Shionogi & Co. Ltd.
  • Merck & Co.
  • Galapagos NV
  • MediciNova Inc.

第11章 結論

附錄

目錄
Product Code: PHA0599

The global anti-idiopathic pulmonary fibrosis drugs market is expected to grow at a CAGR of 16.7% in the first half of the forecast period. In 2018, the anti-fibrotics held the largest market share (51%) followed by the tyrosine kinase inhibitors.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 171-page report you will receive 69 tables and 97 figures- all unavailable elsewhere.

The 171-page report provides clear detailed insight into the global anti-idiopathic pulmonary fibrosis drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

Global Anti-Idiopathic Pulmonary Fibrosis Drugs market forecasts to 2029

This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by mechanism of action:

  • Antifibrotics
  • Tyrosine Kinase Inhibitors
  • Anti-inflammatory Drugs
  • Immunosuppressants
  • Other MoA

This report also breaks down the revenue forecast for the global anti-idiopathic pulmonary fibrosis drugs market by Innovator and Off-label drugs:

  • Innovator Drugs
  • Off-label Drugs

This report provides individual revenue forecasts to 2029 for these national markets:

  • US
  • Japan
  • EU5: Germany, France, the UK, Italy, Spain
  • Rest of World

This report provides individual revenue forecasts to 2029 for these marketed drugs:

  • Esbriet
  • Ofev

Our study gives qualitative analysis of the anti-idiopathic pulmonary fibrosis drugs market. It discusses:

  • Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the G7 markets
  • Epidemiology of Idiopathic Pulmonary Fibrosis by disease severity
  • Epidemiology of Idiopathic Pulmonary Fibrosis by gender
  • Discussion on novel clinical molecules under development for the treatment of Idiopathic Pulmonary Fibrosis
  • Pricing and Reimbursement Overview on Ofev and Esbriet (by NICE, SMC, PBAC, CADTH, G-BA, HAS)
  • A SWOT Analysis on the anti-idiopathic pulmonary fibrosis drugs market

Our study discusses the marketed anti-idiopathic pulmonary fibrosis drugs and pipeline anti-idiopathic pulmonary fibrosis drugs from these companies:

  • Actelion
  • Afferent Pharmaceuticals
  • Asahi Kasei Pharma
  • Bellerophon Therapeutics
  • Biogen
  • Boehringer Ingelheim
  • FibroGen
  • Galapagos
  • Galecto Biotech
  • Genentech
  • Global Blood Therapeutics
  • GSK
  • Kadmon Pharmaceuticals
  • LTT Bio-Pharma
  • MediciNova
  • Merck
  • Moerae
  • Pacific Therapeutics
  • Promedior
  • ProMetic Life Sciences
  • Roche
  • Sanofi
  • Teva
  • Zai Lab

Visiongain's study is intended for anyone requiring commercial analyses for the global Anti-Idiopathic Pulmonary Fibrosis Drugs Market. You find data, trends and predictions.

Table of Contents

1. Report Overview

  • 1.1 Why You Should Read This Report
  • 1.2 How This Report Delivers
  • 1.3 Key Questions Answered by This Analytical Report Include:
  • 1.4 Who is This Report For?
  • 1.5 Methodology
    • 1.5.1 Primary Research
    • 1.5.2 Secondary Research
    • 1.5.3 Market Evaluation & Forecasting Methodology
  • 1.6 Frequently Asked Questions (FAQ)
  • 1.7 Associated Visiongain Reports
  • 1.8 About Visiongain

2. Introduction to the Idiopathic Pulmonary Fibrosis (IPF)

  • 2.1 What is IPF?
  • 2.2 Aetiology - Causes and Risk Factors
  • 2.3 Symptoms
  • 2.4 Stages of IPF
  • 2.5 Diagnosis
    • 2.5.1 Diagnostic Tests
    • 2.5.2 Pulmonary Function Testing/Lung Function Testing
    • 2.5.3 Oximetry
    • 2.5.4 Lung Biopsy
    • 2.5.5 Chest X-ray
    • 2.5.6 Computerized Tomography (CT)
    • 2.5.7 Echocardiogram
  • 2.6 Epidemiology
    • 2.6.1 Methodology
    • 2.6.2 Epidemiology by Country
    • 2.6.3 Epidemiology by Disease Severity
    • 2.6.4 Epidemiology by Gender
    • 2.6.5 Historical Prevalence in Major Markets
    • 2.6.1 Forecast of IPF in Major Markets: 2019-2029
      • 2.6.1.1 The U.S.
      • 2.6.1.2 France
      • 2.6.1.3 Germany
      • 2.6.1.4 The United Kingdom
      • 2.6.1.5 Italy
      • 2.6.1.6 Spain
      • 2.6.1.7 Japan
  • 2.7 Humanistic and Economic Burden
    • 2.7.1 Co-morbidities
    • 2.7.2 Mortality
    • 2.7.3 Healthcare Utilization & Economic Burden
  • 2.8 Prevention and Treatment
    • 2.8.1 Guidelines
    • 2.8.2 Non-pharmacologic Management
      • 2.8.2.1 Quit Smoking
      • 2.8.2.2 Oxygen therapy
      • 2.8.2.3 Pulmonary Rehabilitation
      • 2.8.2.4 Vaccination
      • 2.8.2.5 Maintain Healthy Weight
      • 2.8.2.6 Lung Transplantation
    • 2.8.3 Pharmacologic Treatments

3. Introduction to the Global Anti- Anti-Idiopathic Pulmonary Fibrosis Drugs Market

  • 3.1 Market Structure
  • 3.2 Market Definition and Scope
  • 3.3 Classification by Mechanism of Action
    • 3.3.1 Anti-fibrotics
    • 3.3.2 Tyrosine Kinase Inhibitors
    • 3.3.3 Anti-inflammatory Drugs
    • 3.3.4 Immunosuppressant
    • 3.3.5 Other Mechanisms
  • 3.4 Classification by Innovator or Off-label Drugs
    • 3.4.1 Innovator Drugs
    • 3.4.2 Off-label Drugs

4. Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast to 2029

  • 4.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market 2018
  • 4.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2019-2029
  • 4.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action
  • 4.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Mechanism of Action: Forecast 2019-2029
    • 4.4.1 Global Anti-fibrotics Drugs Market Forecast, 2019-2029
    • 4.4.2 Global Tyrosine Kinase Inhibitors Drugs Market Forecast, 2019-2029
    • 4.4.3 Global Anti-inflammatory Drugs Market Forecast, 2019-2029
    • 4.4.4 Global Immunosuppressant Drugs Market Forecast, 2019-2029
    • 4.4.5 Other MoA Drugs Market Forecast, 2019-2029
    • 4.4.6 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Mechanism of Action: Share Forecast 2019-2029
  • 4.5 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Innovator and Off-label Drugs, 2018
    • 4.5.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Innovator and Off-label drugs: Forecast 2019-2029
      • 4.5.1.1 Global Innovator Drugs Market Forecast, 2019-2029
      • 4.5.1.2 Global Off-label Drugs Market Forecast, 2019-2029
    • 4.5.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Generics: Share Forecast 2019-2029
  • 4.6 Overall Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Drivers, Restraints and Trends

5. Leading Anti-Idiopathic Pulmonary Fibrosis Drugs

  • 5.1 Snapshot of Anti-Idiopathic Pulmonary Fibrosis Drugs Sales, Historical Sales, & Forecast 2019-2029
    • 5.1.1 Esbriet
      • 5.1.1.1 Esbriet: Drug Profile
      • 5.1.1.2 Esbriet: Historical Sales
      • 5.1.1.3 Esbriet Sales Forecast 2019-2029
      • 5.1.1.4 Esbriet Sales by Geography, 2018
    • 5.1.2 Ofev
      • 5.1.2.1 Ofev: Drug Profile
      • 5.1.2.2 Ofev: Historical Sales
      • 5.1.2.3 Ofev: Forecast 2019-2029
      • 5.1.2.4 Ofev: Sales by Geography, 2016
  • 5.2 Off-label Drugs

6. Leading National Markets Forecast to 2029

  • 6.1 Geographical Breakdown of Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2018
  • 6.2 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region, 2019-2029
  • 6.3 The U.S. Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2018
    • 6.3.1 The U.S. Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029
  • 6.4 EU5 Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2018
    • 6.4.1 EU5 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029
      • 6.4.1.1 Germany Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029
      • 6.4.1.2 U.K. Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029
      • 6.4.1.3 France Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029
      • 6.4.1.4 Spain Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029
      • 6.4.1.5 Italy Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029
  • 6.5 Japan Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029
  • 6.6 RoW Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast, 2019-2029

7. Research and Development for Treating IPF

  • 7.1 Novel Mechanism of Action of Pipeline Drugs
  • 7.2 Active Pipeline Molecules
  • 7.3 Promising Potential Pipeline Molecules
    • 7.3.1 Phase III Molecules
      • 7.3.1.1 Recomodulin (ART-123)
    • 7.3.2 Phase II Molecule
      • 7.3.2.1 Pamrevlumab (FG-3019)
      • 7.3.2.2 PRM-151
      • 7.3.2.3 Erivedge (Vismodegib)
      • 7.3.2.4 Opsumit (Macitentan)
      • 7.3.2.5 INOpulse
      • 7.3.2.6 GBT-440
      • 7.3.2.7 TipelU.K.ast (MN-001)
      • 7.3.2.8 TD-139
      • 7.3.2.9 BG00011 (STX-100)
      • 7.3.2.10 LT-1001 & LT-1002
      • 7.3.2.11 KD-025 (SLx-2119)
      • 7.3.2.12 SAR 156597
      • 7.3.2.13 PBI4050
      • 7.3.2.14 MK-7264(AF 219)
      • 7.3.2.15 Lebrikizumab
      • 7.3.2.16 GLPG-1690
    • 7.3.3 Phase I trial
      • 7.3.3.1 PXS 4728A
      • 7.3.3.2 PTL 202
      • 7.3.3.3 GSK3008348
      • 7.3.3.4 Omipalisib (GSK-2126458)
      • 7.3.3.5 MMI-0100
      • 7.3.3.6 Deupirfenidone(SD 560)
      • 7.3.3.7 ZL 2012

8. Pricing and Reimbursement Overview

  • 8.1 Ofev
    • 8.1.1 NICE (U.K.)
    • 8.1.2 SMC (Scotland)
    • 8.1.3 PBAC (Australia)
    • 8.1.4 CADTH (Canada)
    • 8.1.5 G-BA (Germany)
    • 8.1.6 HAS (France)
    • 8.1.7 Overall HTA Challenges
  • 8.2 Esbriet
    • 8.2.1 NICE (U.K.)
    • 8.2.2 SMC (Scotland)
    • 8.2.3 G-BA (Germany)
    • 8.2.4 HAS (France)
    • 8.2.5 CADTH (Canada)

9. Qualitative Analysis of the Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market

  • 9.1 SWOT Analysis

10. Leading Companies in the Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2018

  • 10.1 Roche
    • 10.1.1 Company Profiles
    • 10.1.2 Roche Holding AG
    • 10.1.3 Roche Holding AG: Product Portfolio
    • 10.1.4 Recent Developments
  • 10.2 Boehringer Ingelheim GmbH
    • 10.2.1 Boehringer Ingelheim: Product Portfolio
    • 10.2.2 Recent Developments
  • 10.3 Shionogi & Co. Ltd.
    • 10.3.1 Shionogi & Co. Ltd.: Product Portfolio
    • 10.3.2 Recent Developments
  • 10.4 Merck & Co.
    • 10.4.1 Recent Developments
  • 10.5 Cipla Limited
    • 10.5.1 Cipla Limited: Product Portfolio
    • 10.5.2 Recent Developments
  • 10.6 Galapagos NV
    • 10.6.1 Galapagos NV: Product Portfolio
  • 10.7 MediciNova Inc.
    • 10.7.1 MediciNova Inc.: Product Portfolio

11. Conclusions

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Table

  • Table 2.1: GAP Index for IPF
  • Table 2.2: GAP Staging for IPF
  • Table 2.3: Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016 (absolute cases)
  • Table 2.4: Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis by Severity, ages 40+, 2016 (absolute cases)
  • Table 2.5 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the U.S., ages 40+: absolute cases, AGR (%), CAGR (%), 2019-2029
  • Table 2.6 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the U.S., ages 40+: absolute cases, AGR (%), CAGR (%), 2019-2029
  • Table 2.7 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in France, ages 40: absolute cases, AGR (%), CAGR (%), 2019-2029
  • Table 2.8 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Germany, ages 40+: absolute cases, AGR (%), CAGR (%), 2019-2029
  • Table 2.9 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the U.K., ages 40+: absolute cases, AGR (%), CAGR (%), 2019-2029
  • Table 2.10 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Italy, ages 40+: absolute cases, AGR (%), CAGR (%), 2019-2029
  • Table 2.11 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Spain, ages 40+: absolute cases, AGR (%), CAGR (%), 2019-2029
  • Table 2.12 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Japan, ages 40+: absolute cases, AGR (%), CAGR (%), 2019-2029
  • Table 3.1: Anti-fibrotic molecular targets and pharmacologic agents
  • Table 3.2 Mechanism of Action of Innovator Drugs for the treatment of IPF
  • Table 4.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Markets by Segmentation: Revenue ($m), and Market Share (%), 2018
  • Table 4.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2019-2029: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action 2019-2029: Revenue ($m), AGR (%), CAGR (%)
  • Table 4.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action: AGR (%), 2019-2029
  • Table 4.5 Global Ant fibrotic Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.6 Global Tyrosine Kinase Inhibitor Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.7 Global Anti-inflammatory Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.8 Global Immunosuppressant Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.9 Global Other MoA Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.10 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action: Market Share (%), 2019-2029
  • Table 4.11 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator and Off-label Drugs: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.12 Global Anti-Idiopathic Pulmonary Fibrosis Innovator Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.13 Global Anti-Idiopathic Pulmonary Fibrosis Off-label Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 4.14 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Generics: Market Share (%), 2019-2029
  • Table 5.1 Branded Anti-Idiopathic Pulmonary Fibrosis Drugs
  • Table 5.2 Leading Anti-Idiopathic Pulmonary Fibrosis Drug Sales, Revenue ($m), Market Share (%), 2018
  • Table 5.3 Esbriet: Drug Profile
  • Table 5.4 Esbriet Sales Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 5.5 Ofev: Drug Profile
  • Table 5.6 Ofev Sales Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 6.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Revenue ($m), and Market Share (%), 2018
  • Table 6.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 6.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: AGR (%), 2019-2029
  • Table 6.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region: Market Share (%), 2019-2029
  • Table 6.5 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the U.S. 2019-2029: Revenue ($m), AGR (%), CAGR (%)
  • Table 6.6 Anti-Idiopathic Pulmonary Fibrosis Drugs in the EU5 region: Revenue ($m), Global Market Share (%), EU5 Market Share (%), 2018
  • Table 6.7 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in EU5 Region: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 6.8 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: Market Share (%), 2019-2029
  • Table 6.9 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: AGR (%), 2019-2029
  • Table 6.10 Germany Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 6.11 The U.K. Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 6.12 France Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 6.13 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in Spain: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 6.14 Italy Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 6.15 Japan nti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 6.16 RoW Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), CAGR (%), 2019-2029
  • Table 7.1: Active Pipeline Molecules under Development for Treating IPF
  • Table 7.2: Pamrevlumab - Completed and Ongoing Clinical Trials
  • Table 8.1 Ofev: HTA Agencies' Decision Outcomes
  • Table 8.2 Esbriet: HTA Agencies' Decision Outcomes
  • Table 10.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Market Share (%), 2018
  • Table 10.2 Roche Holding AG: Overview, 2018
  • Table 10.3 Anti-Idiopathic Pulmonary Fibrosis Drug Offerings
  • Table 10.4 Boehringer Ingelheim: Overview, 2018
  • Table 10.5 Anti-Idiopathic Pulmonary Fibrosis Drug Offerings
  • Table 10.6 Shionogi Seiyaku: Overview, 2018
  • Table 10.7 Anti-Idiopathic Pulmonary Fibrosis Drug Offerings
  • Table 10.8 Merck & Co.: Overview, 2018
  • Table 10.9 Cipla Limited: Overview, 2018
  • Table 10.10 Anti-Idiopathic Pulmonary Fibrosis Drug Offerings
  • Table 10.11 Galapagos NV: Overview, 2018
  • Table 10.12 Anti-Idiopathic Pulmonary Fibrosis Drug Offerings
  • Table 10.13 MediciNova Inc.: Overview, 2018
  • Table 10.14 Anti-Idiopathic Pulmonary Fibrosis Drug Offerings

List of Figure

  • Figure 1.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation Overview
  • Figure 2.1: Types of Idiopathic Interstitial Pneumonias
  • Figure 2.2: Pathogenesis of Idiopathic Pulmonary Fibrosis
  • Figure 2.3 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016 (absolute cases)
  • Figure 2.4 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016 (%)
  • Figure 2.5 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis by Severity, ages 40+, 2016 (%)
  • Figure 2.6 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis by Gender in G7 Markets, ages 40+, 2016 (%)
  • Figure 2.7 Historical Prevalence of IPF in G7 Markets, absolute cases; 2010-2015
  • Figure 2.8 Historical Prevalence of IPF in G7 Markets, CAGR, 2010-2015
  • Figure 2.9 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the U.S., ages 40+: absolute cases, AGR (%), 2019-2029
  • Figure 2.10 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in France, ages 40+: absolute cases, AGR (%), 2019-2029
  • Figure 2.11 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Germany, ages 40+: absolute cases, AGR (%), 2019-2029
  • Figure 2.12 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in the U.K., ages 40+: absolute cases, AGR (%), 2019-2029
  • Figure 2.13 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Italy, ages 40+: absolute cases, AGR (%), 2019-2029
  • Figure 2.14 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Spain, ages 40+: absolute cases, AGR (%), 2019-2029
  • Figure 2.15 Forecast of Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in Japan, ages 40+: absolute cases, AGR (%), 2019-2029
  • Figure 2.16: Comparison of Recommendations in the 2015 and 2011 Idiopathic Pulmonary Fibrosis Guidelines
  • Figure 3.1 Anti-Idiopathic Pulmonary Fibrosis Drugs Classification by Mechanism of Action, 2018
  • Figure 3.2: Inflammatory Pathway in IPF
  • Figure 4.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2019-2029: Revenue ($m), AGR (%)
  • Figure 4.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action 2018, Revenue ($m)
  • Figure 4.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action: Market Share (%), 2018
  • Figure 4.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action 2019-2029: Revenue ($m), AGR (%)
  • Figure 4.5 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action 2018 and 2029: Revenue ($m), CAGR (%), 2018 and 2018
  • Figure 4.6 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action: AGR (%), 2019-2029
  • Figure 4.7 Global Ant fibrotic Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.8 Global Tyrosine Kinase Inhibitor Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.9 Global Anti-inflammatory Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.10 Global Immunosuppressant Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.11 Global Other MoA Drugs Market: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.12 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Mechanism of Action: Market Share (%), 2019-2029
  • Figure 4.13 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action: Market Share Forecast (%), 2018
  • Figure 4.14 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Mechanism of Action: Market Share (%), 2029
  • Figure 4.15 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Innovator and Off-label Drugs: Revenue ($m), 2018
  • Figure 4.16 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Innovator and Off-label Drugs: Market Share (%), 2018
  • Figure 4.17 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Off-label drugs: Revenue ($m), Global AGR (%), 2019-2029
  • Figure 4.18 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator and Off-label Drugs: Revenue 2018 and 2029 ($m), CAGR 2019-2029 (%)
  • Figure 4.19 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator and Off-label Drugs: AGR (%), 2019-2029
  • Figure 4.20 Global Anti-Idiopathic Pulmonary Fibrosis Innovator Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.21 Global Anti-Idiopathic Pulmonary Fibrosis Off-label Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 4.22 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Innovator Drugs and Generics: Market Share (%), 2019-2029
  • Figure 4.23 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Innovator and Off-label Drugs: Market Share (%), 2018
  • Figure 4.24 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Innovator and Off-label Drugs: Market Share (%), 2029
  • Figure 4.25 Trends in Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016
  • Figure 4.26 Trends in Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2018
  • Figure 5.1 Leading Anti-Idiopathic Pulmonary Fibrosis Drugs Sales, Revenue ($m), 2018
  • Figure 5.2 Leading Anti-Idiopathic Pulmonary Fibrosis Drug Sales, Market Share (%), 2018
  • Figure 5.3 Anti-Idiopathic Pulmonary Fibrosis Sales Forecast, Market Share (%), 2029
  • Figure 5.4 Global Anti-Idiopathic Pulmonary Fibrosis Sales Forecast, Ofev and Esbriet, Revenue ($m), 2019-2029
  • Figure 5.5 Leading Anti-Idiopathic Pulmonary Fibrosis Drugs, Historical Sales, Revenue ($m), 2011-2016
  • Figure 5.6 Anti-Idiopathic Pulmonary Fibrosis Drugs, Historical Sales Trend, Revenue ($m), 2011-2016
  • Figure 5.7 Esbriet Global Sales: Revenue ($million), 2011-2016
  • Figure 5.8 Global Anti-Idiopathic Pulmonary Fibrosis Off-label Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 5.9 Esbriet Sales Forecast 2019-2029: Revenue ($million), AGR (%)
  • Figure 5.10 Esbriet Sales by Geography: Revenue ($m), 2018
  • Figure 5.11 Esbriet Sales by Geography: Market Share (%), 2018
  • Figure 5.12 Ofev Global Sales: Revenue ($m), 2014-2016
  • Figure 5.13 Global Anti-Idiopathic Pulmonary Fibrosis Off-label Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 5.14 Ofev Sales Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 5.15 Ofev Sales by Geography: Revenue ($m), 2018
  • Figure 5.16 Ofev Sales by Geography: Market Share (%), 2018
  • Figure 5.17 Global Anti-Idiopathic Pulmonary Fibrosis Off-label drugs Market: Market Share by Individual Compound (%), 2018
  • Figure 6.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Segmentation by Region/Country
  • Figure 6.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Revenue ($m), 2018
  • Figure 6.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Market Share 2018 (%)
  • Figure 6.4 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region: Revenue ($m), AGR (%), 2019-2029
  • Figure 6.5 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region 2018, 2024, 2029: Revenue ($m), CAGR 2019-2029 (%)
  • Source: Visiongain 2019
  • Figure 6.6 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: AGR (%), 2019-2029
  • Figure 6.7 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by Region: Market Share (%), 2019-2029
  • Figure 6.8 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Market Share Forecast 2018 (%)
  • Figure 6.9 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Market Share Forecast 2024 (%)
  • Figure 6.10 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Region: Market Share Forecast 2029 (%)
  • Figure 6.11 Anti-Idiopathic Pulmonary Fibrosis Drugs Market in the U.S.: 2018 Revenue ($m), Market Share %
  • Figure 6.12 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the U.S. 2019-2029: Revenue ($m), AGR (%)
  • Figure 6.13 Anti-Idiopathic Pulmonary Fibrosis Drugs Market in the EU5: Global Market Share (%), 2018
  • Figure 6.14 Anti-Idiopathic Pulmonary Fibrosis Drugs Market in the EU5 Countries: Market Share (%), 2018
  • Figure 6.15 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the EU5 Countries: Revenue ($m), EU5 AGR (%), 2019-2029
  • Figure 6.16 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in the EU5 Countries 2018 and 2029: Revenue ($m), CAGR 2019-2029 (%)
  • Figure 6.17 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: Market Share (%), 2019-2029
  • Figure 6.18 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast by EU5 Region: AGR (%), 2019-2029
  • Figure 6.19 Germany Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 6.20 The U.K. Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 6.21 France Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 6.22 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in Spain: Revenue ($m), AGR (%), 2019-2029
  • Figure 6.23 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in Italy: Revenue ($m), AGR (%), 2019-2029
  • Figure 6.24 Japan Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast: Revenue ($m), AGR (%), 2019-2029
  • Figure 6.25 Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast in RoW: Revenue ($m), AGR (%),2019-2029
  • Figure 7.1 Anti-Idiopathic Pulmonary Fibrosis Clinical Pipeline Segmentation by Phase, 2018
  • Figure 7.2 Key Molecular Targets of Idiopathic Pulmonary Fibrosis
  • Figure 7.3 Recomodulin - Mechanism of Action
  • Figure 9.1 SWOT Analysis of the Anti-Idiopathic Pulmonary Fibrosis Drugs Market, 2016
  • Figure 10.1 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Revenue ($m), 2018
  • Figure 10.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Market Share (%), 2018
  • Figure 10.3 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market by Company: Revenue ($m) 2016
  • Figure 11.1 Diagnosed Prevalence of Idiopathic Pulmonary Fibrosis in G7 Markets, ages 40+, 2016 (%)
  • Figure 11.2 Global Anti-Idiopathic Pulmonary Fibrosis Drugs Market Forecast 2019-2029: Revenue ($m), AGR (%)

List of Companies and Organizations Mentioned in the Report:

  • Actelion
  • Afferent Pharmaceuticals
  • American Thoracic Society (ATS)
  • Asahi Kasei Pharma
  • Auspex Pharmaceuticals
  • Bellerophon Therapeutics
  • Biogen Idec.
  • BMS
  • Boehringer Ingelheim
  • Canadian Agency for Drugs and Technologies in Health (CADTH) (Canada)
  • Curis
  • European Commission
  • European Respiratory Society (ERS)
  • FDA
  • FibroGen
  • Galapagos
  • Galecto
  • Genentech
  • Global Blood Therapeutics
  • Haute Autorité de Santé (HAS) (France)
  • Ikaria
  • Ildong Pharmaceutical Co., Ltd.
  • Institut für Qualität und Wirtschaftlichkeit im Gesundheitswesen (IQWiG) (Germany)
  • IntelGenX
  • InterMune
  • Janssen
  • Japanese Respiratory Society (JRS)
  • Kadmon Corporation
  • Kadmon Holdings
  • Kedem Pharmaceuticals
  • Kyorin
  • Latin American Thoracic Association (ALAT)
  • LTT Bio-Pharma
  • MediciNova
  • Merck
  • MicroDose Therapeutx
  • Moerae Matrix
  • Nano Terra
  • National Institute for Health and Care Excellence (NICE)
  • Nippon Shinyaku
  • Pacific Therapeutics
  • Pharmaceutical Benefits Advisory Committee (PBAC) (Australia)
  • Pharmaxis
  • Promedior
  • ProMetic Life Sciences
  • Quintiles
  • Roche
  • Sanofi
  • Scottish Medicines Consortium (SMC) (Scotland)
  • Shionogi & Co., Ltd
  • Stromedix Inc.
  • Synairgen
  • Teva
  • Zai Lab